ClinicalTrials.Veeva

Menu

Epidemiology of Vascular Inflammation & Atherosclerosis

University of Vermont logo

University of Vermont

Status

Completed

Conditions

Cerebrovascular Accident
Coronary Arteriosclerosis
Cerebral Arteriosclerosis
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Atherosclerosis

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT00087893
1261
R01HL077449 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

To investigate the relationship of vascular cell phenotypes to atherosclerosis.

Full description

BACKGROUND:

Currently, the predominant hypothesis regarding atherosclerosis is that it is in major part driven by two independent pathways: hyperlipidemia (the "stimulation") and inflammation (the "response"). Although vascular cells mediate the influence of inflammation on atherosclerosis, very little is known about vascular cell epidemiology and the relationship of vascular cell phenotypes to atherosclerosis. The main hypothesis tested in this study is that variation in vascular cell biology is related to the population variation in atherosclerosis.

DESIGN NARRATIVE:

The cross-sectional study will be nested within a large cohort study, the Multiethnic Study of Atherosclerosis (MESA). A partial sample of 1,000 individuals who have undergone other special laboratory analyses will be identified and new measures collected as part of their upcoming site visit. A number of novel cellular phenotypes describing the innate immune response (monocyte activation, natural killer and T cell counts), the adaptive immune response (TH1 and TH2 helper cells, and memory T cells), and vessel integrity (circulating endothelial progenitor cells) will be measured in these participants. Plasma constituents will also be measured that relate to the cellular phenotypes. The overall goal is to test the hypothesis that these novel phenotypes are associated with subclinical atherosclerosis in the coronary and carotid arteries assessed by quantification of coronary calcification (CAC) and B-mode ultrasound (CIMT), in addition to the other subclinical measures available from the MESA cohort.

Enrollment

931 patients

Sex

All

Ages

45 to 84 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

No eligibility criteria

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems